A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

The goal of this clinical trial is to learn if golidocitinib combined with tislelizumab and chemotherapy works in advanced NSCLC with PD-L1≥1%. The main question it aims to answer is: Does the combination of golidocitinib with tislelizumab and chemotherapy can prolong the progression-free survival of patients with advanced NSCLC? Participants will： Take tislelizumab and chemotherapy for 2 cycles; and then take tislelizumab and golidocitinib for 2 cycles; after cycle 5, patients receive tislelizumab and chemotherapy until the patients were intolerant or the disease progressed.

Trial Details

NCT ID

NCT06969612

Phase

PHASE1

Sponsor

Peking University Cancer Hospital & Institute

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Tislelizumab
Pemetrexed
Cisplatin
Carboplatin
Paclitaxel
Albumin Paclitaxel

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Be able to provide the informed consent form with signatures and signing dates, including compliance with the requirements and restrictions listed …
At the time of signing the ICF, the age must be at least 18 years old, with no gender restrictions.
The ECOG score is 0 or 1.
Life expectancy ≥ 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →